Prognostic value of PD-L1 expression in patients with pancreatic cancer

Abstract

Background:Programmed cell death ligand 1 (PD-L1) expression was reported to be associated with poor prognosis in various solid tumors. However, the prognosis value of PD-L1 in pancreatic cancer remained inconclusive. We performed a meta-analysis to assess the clinical value of PD-L1 as a novel prognostic biomarker of pancreatic cancer.Methods:PubMed, Embase, and Web of Science were searched up to October 2018. The HRs and 95% CIs for overall survival (OS) and cancer-specific survival (CSS) according to the expressional status of PD-L1 were pooled. The combined odd ratios (ORs) and 95% CIs were utilized to assess the association between PD-L1 and clinicopathological characteristics.Results:A total of 9 studies with 993 patients were included. Elevated PD-L1 expression was related with poor OS (HR = 1.63, 95% CI = 1.34–1.98, P < .001) and CSS (HR = 1.86, 95% CI = 1.34–2.57, P < .001). Furthermore, high PD-L1 expression was also demonstrated to be associated with positive N stage (OR = 1.81, 95% CI = 1.21–2.71, P = .004), advanced T stage (OR = 1.86, 95% CI = 1.08–3.19, P = .025), and low differentiation (OR = 2.24, 95% CI = 1.16–4.33, P = .017). However, PD-L1 has nonsignificant correlation with M stage, gender, or age.Conclusion:This study suggests that PD-L1 is a potential prognostic biomarker and may be helpful to clinicians aiming to select the appropriate immunotherapy for pancreatic cancer.

Association of PD-L1 Expression with Prognosis Among Patients with Ten Uncommon Advanced Cancers

“…Results from the current retrospective longitudinal study suggest that PD-L1 expression is associated with shorter OS after first-line SOC therapy (nonimmunotherapy) across a range of tumors (unadjusted HR: 1.39 [95% CI: 1.07–1.81]; p = 0.0136). Consistent with our findings, previous studies have identified an association of PD-L1 expression with shorter OS in patients with malignant salivary gland tumor [ 31 ], malignant pleural mesothelioma [ 32 ], NSCLC [ 30 , 33 ] and pancreatic cancer [ 30 , 34 ]. In contrast, other studies have reported that PD-L1 expression was associated with longer OS in patients with NSCLC [ 35 ] and SCLC [ 36 ].…”

Prognostic and Clinicopathological Role of PD-L1 in Endometrial Cancer: A Meta-Analysis

“…Furthermore, high PD-L1 was significantly correlated with later tumor stages (OR = 3.9, 95%CI = 2.71.5.61, p < 0.001) and distant metastases (OR = 2.5, 95%CI = 1.22.5.1, p = 0.012) in bladder cancer (29). Another meta-analysis on non-small cell lung cancer (NSCLC) showed that PD-L1 expression was significantly associated with histology type, differentiation, and tumor stage, whereas the relationship between PD-L1 expression and OS was not statistically significant (p = 0.863) (30). Similar to this study on NSCLC (30), we also found an association between PD-L1 and differentiation and tumor stage in EC, whereas the prognostic effect of PD-L1 on survival was not significant.…”

Prognostic and Clinicopathological Significance of PD-L1 in Patients With Bladder Cancer: A Meta-Analysis

“…Li’s study showed that PD-L1 overexpression could foresee worse OS and DFS in hepatocellular carcinoma (Li et al, 2018a). In addition, another meta-analysis comprising a total of nine studies with 993 patients demonstrated that elevated PD-L1 expression was related with poor OS (HR = 1.63, 95% CI = 1.34–1.98, p < .001) and CSS (HR = 1.86, 95% CI = 1.34–2.57, p < .001) in pancreatic cancer (Hu et al, 2019). High PD-L1 expression was also correlated with poor OS in breast cancer (Zhang et al, 2017).…”